Melinda S Merchant

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors
    Melinda S Merchant
    National Cancer Institute, National Institutes of Health, 10 Center Dr, Building 10 CRC, Room 1W 3750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 30:4141-7. 2012
  2. ncbi request reprint Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity
    Melinda S Merchant
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 94:1673-9. 2002
  3. doi request reprint Current approach to pediatric soft tissue sarcomas
    Melinda S Merchant
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 14:1139-53. 2009
  4. ncbi request reprint Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma
    Melinda S Merchant
    Pediatric Oncology Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 64:8349-56. 2004
  5. ncbi request reprint Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression
    Kiichiro Beppu
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:46-55. 2004
  6. ncbi request reprint Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB
    Xuezhong Yang
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 63:1122-9. 2003
  7. doi request reprint Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
    Melinda S Merchant
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH Clinical Center, Bethesda, Maryland
    Clin Cancer Res 22:3182-91. 2016
  8. ncbi request reprint Immune reconstitution prevents metastatic recurrence of murine osteosarcoma
    Melinda S Merchant
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 56:1037-46. 2007
  9. doi request reprint Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health NIH, Bethesda, Maryland
    Pediatr Blood Cancer 63:997-1005. 2016
  10. pmc Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
    Melinda S Merchant
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    Clin Cancer Res 22:1364-70. 2016

Collaborators

Detail Information

Publications15

  1. pmc Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors
    Melinda S Merchant
    National Cancer Institute, National Institutes of Health, 10 Center Dr, Building 10 CRC, Room 1W 3750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 30:4141-7. 2012
    ..Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2 with preclinical evidence of activity in pediatric solid tumors...
  2. ncbi request reprint Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity
    Melinda S Merchant
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 94:1673-9. 2002
    ..We thus examined whether the specific tyrosine kinase inhibitor imatinib mesylate (hereafter imatinib; formerly STI571) could inhibit the proliferation of Ewing's sarcoma cells in vitro and in vivo...
  3. doi request reprint Current approach to pediatric soft tissue sarcomas
    Melinda S Merchant
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 14:1139-53. 2009
    ..This review focuses on the current recommendations for management of sarcomas that typically occur in the soft tissues of pediatric and young adult patients...
  4. ncbi request reprint Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma
    Melinda S Merchant
    Pediatric Oncology Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 64:8349-56. 2004
    ....
  5. ncbi request reprint Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression
    Kiichiro Beppu
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:46-55. 2004
    ..We therefore evaluated the effects of imatinib mesylate (imatinib), a selective inhibitor of the tyrosine kinase activities of c-Kit and PDGFR, on the growth of neuroblastoma cells in vivo and in vitro...
  6. ncbi request reprint Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB
    Xuezhong Yang
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 63:1122-9. 2003
    ..Furthermore, we have found that we can improve TRAIL sensitivity in NB by reconstituting caspase 8 with IFN-gamma and TR2 with chemotherapeutic agents...
  7. doi request reprint Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
    Melinda S Merchant
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH Clinical Center, Bethesda, Maryland
    Clin Cancer Res 22:3182-91. 2016
    ..We administered adjuvant immunotherapy to patients with metastatic and recurrent pediatric sarcomas in an effort to improve outcomes...
  8. ncbi request reprint Immune reconstitution prevents metastatic recurrence of murine osteosarcoma
    Melinda S Merchant
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 56:1037-46. 2007
    ..The results further suggest that T cell depleting cancer therapies may eliminate beneficial immune responses and that immune reconstitution of lymphopenic cancer patients could prevent metastatic recurrence of solid tumors...
  9. doi request reprint Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health NIH, Bethesda, Maryland
    Pediatr Blood Cancer 63:997-1005. 2016
    ..Pediatric experience with VSLI is limited...
  10. pmc Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
    Melinda S Merchant
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    Clin Cancer Res 22:1364-70. 2016
    ..Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol...
  11. pmc Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells
    David F Stroncek
    Cell Processing Section, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA Electronic address
    Cytotherapy 18:893-901. 2016
    ..Autologous chimeric antigen receptor (CAR) T-cell therapies have shown promising clinical outcomes, but T-cell yields have been variable. CD19- and GD2-CAR T-cell manufacturing records were reviewed to identify sources of variability...
  12. pmc Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
    Blood 125:784-92. 2015
    ..This trial was registered at www.clinicaltrials.gov as #NCT01287104. ..
  13. doi request reprint Immune-based therapies for childhood cancer
    Crystal L Mackall
    Paediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, MSC 1104, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 11:693-703. 2014
    ....
  14. pmc What do parents want to know when considering autopsy for their child with cancer?
    Lori Wiener
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD Memorial Sloan Kettering Cancer Center, New York, NY
    J Pediatr Hematol Oncol 36:464-70. 2014
    ..The future research and clinical implications of these findings are discussed. ..
  15. ncbi request reprint Tumor expression of 4-1BB ligand sustains tumor lytic T cells
    Hua Zhang
    National Cancer Institute Bethesda, Maryland USA
    Cancer Biol Ther 2:579-86. 2003
    ..They further demonstrate a potential new therapeutic role for 4-1BBL mediated costimulation in expanding tumor reactive CTLs for use in the adoptive immunotherapy of cancer...